Sacubitril
drugOn this page
Also known as AHU-377AHU377Sacubitril component of entrestoSacubitriloSACUBITRIL HEMICALCIUM SALTShakubattam
Summary
Sacubitril (CHEMBL3137301) is an approved small molecule; indicated across 13 conditions including congestive heart failure and heart failure.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 13 conditions
- Clinical trials: 72
- Chemistry: 411.5 Da · C24H29NO5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3137301 |
| Name | Sacubitril |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 9811834 |
| Molecular formula | C24H29NO5 |
| Molecular weight | 411.5 |
| InChIKey | PYNXFZCZUAOOQC-UTKZUKDTSA-N |
SMILES: CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)O
IUPAC name: 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid
Also known as: AHU-377, AHU377, Sacubitril, Sacubitril component of entresto, Sacubitrilo, SACUBITRIL, SACUBITRIL HEMICALCIUM SALT, sacubitril, Sacubitril hemicalcium salt, Shakubattam
Patent coverage: 578 distinct patent families (1,401 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
13 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| congestive heart failure | 4 | MONDO:0005009 | EFO:0000373 |
| heart failure | 4 | MONDO:0005252 | EFO:0003144 |
| hypertensive disorder | 3 | MONDO:0005044 | EFO:0000537 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| Chagas cardiomyopathy | 3 | MONDO:0005491 | EFO:0005529 |
| acute myocardial infarction | 3 | MONDO:0004781 | EFO:0008583 |
| ST-elevation myocardial infarction | 3 | MONDO:0041656 | EFO:0008585 |
| pulmonary hypertension | 3 | MONDO:0005149 | MONDO:0005149 |
| hypertrophic cardiomyopathy | 2 | MONDO:0005045 | EFO:0000538 |
| peripheral arterial disease | 2 | MONDO:0005386 | EFO:0004265 |
| aortic valve insufficiency | 2 | MONDO:0005648 | EFO:0007148 |
| essential hypertension | 2 | MONDO:0001134 | MONDO:0001134 |
| severe acute respiratory syndrome | 1 | MONDO:0005091 | MONDO:0100096 |
Clinical trials
Total trials: 72.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 24 |
| Not specified | 22 |
| PHASE3 | 12 |
| PHASE2 | 7 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06218199 | PHASE4 | RECRUITING | Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts |
| NCT06501651 | PHASE4 | NOT_YET_RECRUITING | Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy |
| NCT06704633 | PHASE4 | NOT_YET_RECRUITING | Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania |
| NCT06917664 | PHASE4 | RECRUITING | Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease |
| NCT07241338 | PHASE4 | NOT_YET_RECRUITING | Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity |
| NCT07572032 | PHASE4 | NOT_YET_RECRUITING | Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study |
| NCT02554890 | PHASE4 | COMPLETED | Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. |
| NCT02787798 | PHASE4 | TERMINATED | Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure |
| NCT02788656 | PHASE4 | TERMINATED | Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) |
| NCT02970669 | PHASE4 | COMPLETED | Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. |
| NCT03119623 | PHASE4 | WITHDRAWN | Comparing ARNI With ACE Inhibitor on Endothelial Function |
| NCT03300427 | PHASE4 | COMPLETED | The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients |
| NCT03553303 | PHASE4 | UNKNOWN | Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin |
| NCT04023227 | PHASE4 | COMPLETED | Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC |
| NCT04197050 | PHASE4 | UNKNOWN | Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD |
| NCT04342351 | PHASE4 | UNKNOWN | Early Treatment of ARNI on Myocardial Remodeling and Progress |
| NCT04572724 | PHASE4 | UNKNOWN | The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value |
| NCT04929600 | PHASE4 | UNKNOWN | Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy. |
| NCT05060588 | PHASE4 | UNKNOWN | Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction |
| NCT05243199 | PHASE4 | COMPLETED | Sacubitril/Valsartan for CKD5 Stage Dialysis Patients |
| NCT05387967 | PHASE4 | COMPLETED | Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction |
| NCT05881720 | PHASE4 | COMPLETED | Sacubitril/Valsartan Versus Valsartan in Heart Failure |
| NCT06035978 | PHASE4 | UNKNOWN | Determination of Drug Levels for Pharmacotherapy of Heart Failure |
| NCT07417215 | PHASE4 | COMPLETED | The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF |
| NCT05508035 | PHASE3 | RECRUITING | The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction |
| NCT06712030 | PHASE3 | NOT_YET_RECRUITING | Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction |
| NCT06716970 | PHASE3 | NOT_YET_RECRUITING | QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension |
| NCT03066804 | PHASE3 | COMPLETED | A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients |
| NCT03552575 | PHASE3 | COMPLETED | The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI |
| NCT03785405 | PHASE3 | COMPLETED | Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF |
| NCT03988634 | PHASE3 | COMPLETED | Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) |
| NCT04637555 | PHASE3 | WITHDRAWN | Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) |
| NCT04753112 | PHASE3 | COMPLETED | Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device |
| NCT04853758 | PHASE3 | UNKNOWN | Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF. |
| NCT05366101 | PHASE2/PHASE3 | COMPLETED | Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy |
| NCT05545059 | PHASE3 | UNKNOWN | Effects and Safety of Sacubitril/Valsartan on Refractory Hypertension |
| NCT06149104 | PHASE3 | COMPLETED | A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study |
| NCT07023016 | PHASE2/PHASE3 | COMPLETED | Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure |
| NCT05279742 | PHASE1/PHASE2 | ENROLLING_BY_INVITATION | Enhancing the Natriuretic Peptide System in HFpEF |
| NCT00549770 | PHASE2 | COMPLETED | Efficacy and Safety of LCZ696A in Patients With Essential Hypertension |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).